This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Yttrium 90-labeled ibritumomab tiuxetan radioimmun...
Journal

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

Read time: 1 mins
Published:1st Sep 2004
Author: Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C.
Availability: Pay for access, or by subscription
Ref.:Clin Lymphoma. 2004 Sep;5(2):98-101.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest